178 related articles for article (PubMed ID: 18672640)
1. Hepatic cytochrome P450 2E1 activity in nonalcoholic fatty liver disease.
Prompila N; Wittayalertpanya S; Komolmit P
J Med Assoc Thai; 2008 May; 91(5):733-8. PubMed ID: 18672640
[TBL] [Abstract][Full Text] [Related]
2. A study on the pharmacokinetics of chlorzoxazone in healthy Thai volunteers.
Prompila N; Wittayalertpanya S; Komolmit P
J Med Assoc Thai; 2007 Jan; 90(1):160-6. PubMed ID: 17621748
[TBL] [Abstract][Full Text] [Related]
3. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis.
Chtioui H; Semela D; Ledermann M; Zimmermann A; Dufour JF
Liver Int; 2007 Aug; 27(6):764-71. PubMed ID: 17617119
[TBL] [Abstract][Full Text] [Related]
4. In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene.
Piccoli P; Carrieri M; Padovano L; Di Mare M; Bartolucci GB; Fracasso ME; Lepera JS; Manno M
Toxicol Lett; 2010 Jan; 192(1):29-33. PubMed ID: 19900514
[TBL] [Abstract][Full Text] [Related]
5. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
Nolin TD; Gastonguay MR; Bies RR; Matzke GR; Frye RF
Clin Pharmacol Ther; 2003 Dec; 74(6):555-68. PubMed ID: 14663458
[TBL] [Abstract][Full Text] [Related]
6. Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women.
Varela NM; Quiñones LA; Orellana M; Poniachik J; Csendes A; Smok G; Rodrigo R; Cáceres DD; Videla LA
Biol Res; 2008; 41(1):81-92. PubMed ID: 18769766
[TBL] [Abstract][Full Text] [Related]
7. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.
Emery MG; Fisher JM; Chien JY; Kharasch ED; Dellinger EP; Kowdley KV; Thummel KE
Hepatology; 2003 Aug; 38(2):428-35. PubMed ID: 12883487
[TBL] [Abstract][Full Text] [Related]
8. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis.
Chalasani N; Gorski JC; Asghar MS; Asghar A; Foresman B; Hall SD; Crabb DW
Hepatology; 2003 Mar; 37(3):544-50. PubMed ID: 12601351
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of intravenous chlorzoxazone in rats with dehydration and rehydration: effects of food intakes.
Kim YC; Kim YG; Kim EJ; Cho MK; Kim SG; Lee MG
Biopharm Drug Dispos; 2003 Mar; 24(2):53-61. PubMed ID: 12619050
[TBL] [Abstract][Full Text] [Related]
10. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity.
Dreisbach AW; Ferencz N; Hopkins NE; Fuentes MG; Rege AB; George WJ; Lertora JJ
Clin Pharmacol Ther; 1995 Nov; 58(5):498-505. PubMed ID: 7586943
[TBL] [Abstract][Full Text] [Related]
11. Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics.
Liangpunsakul S; Kolwankar D; Pinto A; Gorski JC; Hall SD; Chalasani N
Hepatology; 2005 May; 41(5):1144-50. PubMed ID: 15841467
[TBL] [Abstract][Full Text] [Related]
12. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis.
Weltman MD; Farrell GC; Hall P; Ingelman-Sundberg M; Liddle C
Hepatology; 1998 Jan; 27(1):128-33. PubMed ID: 9425928
[TBL] [Abstract][Full Text] [Related]
13. Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans.
Mishin VM; Rosman AS; Basu P; Kessova I; Oneta CM; Lieber CS
Am J Gastroenterol; 1998 Nov; 93(11):2154-61. PubMed ID: 9820389
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cytochrome P4502E1 (CYP2E1) activity and hepatic and lymphocyte mRNA expression in patients with chronic hepatitis C.
Haufroid V; Ligocka D; Wallemacq P; Lison D; Horsmans Y
Toxicol Lett; 2005 Jan; 155(1):171-7. PubMed ID: 15585372
[TBL] [Abstract][Full Text] [Related]
15. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats.
Rockich K; Blouin R
Drug Metab Dispos; 1999 Sep; 27(9):1074-7. PubMed ID: 10460809
[TBL] [Abstract][Full Text] [Related]
16. Circadian rhythm of cytochrome P4502E1 and its effect on disposition kinetics of chlorzoxazone in rats.
Khemawoot P; Nishino K; Ishizaki J; Yokogawa K; Miyamoto K
Eur J Pharmacol; 2007 Nov; 574(1):71-6. PubMed ID: 17651723
[TBL] [Abstract][Full Text] [Related]
17. Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe.
Park JY; Kim KA; Park PW; Ha JM
J Clin Pharmacol; 2006 Jan; 46(1):109-14. PubMed ID: 16397290
[TBL] [Abstract][Full Text] [Related]
18. Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers.
Bedada SK; Boga PK
Xenobiotica; 2017 Dec; 47(12):1035-1041. PubMed ID: 27670974
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role.
Aubert J; Begriche K; Knockaert L; Robin MA; Fromenty B
Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):630-7. PubMed ID: 21664213
[TBL] [Abstract][Full Text] [Related]
20. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans.
Poloyac SM; Tosheva RT; Gardner BM; Shedlofsky SI; Blouin RA
Clin Pharmacol Ther; 1999 Dec; 66(6):554-62. PubMed ID: 10613610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
